Privo Technologies, a US-based late-stage clinical biopharmaceutical company, on Monday reported results from the CLN-004 Phase 2/3 (Cohort 1) trial evaluating PRV111, a nanoengineered, cisplatin-releasing patch intended for the treatment of non-invasive oral cancer and high-grade dysplasia (HGD).

In this trial, PRV111 delivered a 92% pathologic complete response (CR) rate, eliminated the requirement for surgery in all patients, and demonstrated durable local control.

The CLN-004 study builds on Privo's earlier clinical experience with PRV111 (CLN-001), which showed promising local tumour responses with no systemic toxicity in a first-in-human setting.

Next, Privo is initiating a registrational study of PRV111 in non-invasive oral cancer and HGD. The company will also explore PRV111 in other early malignant and premalignant lesions where non-surgical alternatives could provide significant benefits.